Clinical Trial Update: Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating visilizumab to prevent graft-versus-host disease after allogeneic hematopoietic cell transplantation was terminated, with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Graft-versus-host Disease

Drugs mentioned

• Visilizumab (visilizumab)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Graft Versus Host Disease | Phase 2 | Status: TERMINATED | Results posted: 2014-07-04